ERYTHROPOETINS UTILIZATION REVIEW IN CORRECTION OF ANEMIA AT PATIENTS WITH DIABETIC NEPHROPATHY WHO ARE TREATED WITH PERITONEAL DIALYSIS
Research of efficiency, safety and shipping of erythropoetins, applied to correction of anemia at patients with diabetic nephropathy in end-stage renal disease receiving replaceable renal therapy by a method peritoneal dialysis was the work purpose. In research have been included 31 patient which throughout 12 months received therapy with use Recormon and Mircera. Initial level of hemoglobin made 65-97 g/L (on the average 81,1±5,92 g/L). The haemoglobin average level by the research end has made 109,5 ± 3,2 g/L; average level of hematocrit - 33,8±2,8 %; Level of arterial pressure was stable, shipping of preparations good. Research has shown erythropoetins utilization at patients with diabetic nephropathy on peritoneal dialysis allows effectively and safely resolve associated anemia.